Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)

NCT04468659 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT04468659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04468659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 14, 2020
Completion date
January 16, 2031
Enrollment
1,400 (estimated)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

early preclinical alzheimer's disease, preclinical alzheimer's disease